USFDA approves 3rd biosimilar: Erelzi, a biosimilar to Enbrel
Posted on02 Sep 2016
TagsBiosimilar, biosimilar of enbrel, black box warning, Erelzi, Etanercept, meaning of black box warning
Comments0
The U.S. Food and Drug Administration today approved Erelzi, for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally... Read More
Sandoz to launch Amgen’s Enbrel Biosimilar
Sandoz, a Novartis company and the global leader in biosimilars, announced that the US Food and Drug Administration (FDA) has accepted its... Read More
Intas Pharma launches first etanercept biosimilar
Intas Pharmaceuticals has launched INTACEPT, the first biosimilar to Amgen’s Enbrel (etanercept). INTACEPT has been launched in two strengths, 25mg in 0.5... Read More